4.2 Article

Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study

Journal

JOURNAL OF NERVOUS AND MENTAL DISEASE
Volume 199, Issue 10, Pages 807-810

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NMD.0b013e31822fcbe2

Keywords

Major depressive disorder; citalopram; social adjustment

Funding

  1. NIMH [N01 MH-90003]
  2. National Institutes of Health
  3. Centers for Disease Control
  4. Kaplen Foundation
  5. Massachusetts General Hospital
  6. Massachusetts General Hospital Physicians Organization
  7. AstraZeneca
  8. Bristol-Meyers Squibb
  9. Cephalon
  10. Janssen
  11. Lilly
  12. Merck
  13. Pfizer
  14. Wyeth
  15. Eli Lilly
  16. Abbott
  17. Alkermes
  18. Aspect Medical Systems
  19. Forest Laboratories
  20. GlaxoSmithKline
  21. Johnson Johnson
  22. Lichtwer Pharma GmbH
  23. Lorex Pharmaceuticals
  24. Novartis
  25. Organon
  26. Pamlab
  27. Pharmavite
  28. Roche
  29. Sanofi-Synthelabo
  30. Solvay
  31. Cyberonic Inc
  32. ImaRx Therapeutics, Inc
  33. Bristol-Myers Squibb Company
  34. Case-Western University
  35. Singapore Clinical Research Institute
  36. Agency for Healthcare Research and Quality (AHRQ)
  37. Corcept Therapeutics Inc
  38. Cyberonics Inc
  39. National Alliance for Research in Schizophrenia and Depression
  40. NIMH
  41. National Institute on Drug Abuse
  42. Pharmacia Upjohn
  43. Predix Pharmaceuticals (Epix)
  44. Solvay Pharmaceuticals Inc
  45. Targacept
  46. Best Practices
  47. American Foundation of Suicide Prevention
  48. ANT North America Inc (Advanced Neuro Technology)
  49. Abbott Laboratories
  50. Alkermes Inc
  51. BioResearch
  52. BrainCells Inc
  53. Cephalon Inc
  54. Clinical Trials Solutions LLC
  55. Covidien
  56. Eli Lilly and Company
  57. EnVivo Pharmaceuticals Inc
  58. Forest Pharmaceuticals Inc
  59. Ganeden Biotech Inc
  60. Johnson & Johnson Pharmaceutical Research Development
  61. Novartis AG
  62. Organon Pharmaceuticals
  63. PamLab LLC
  64. Pfizer Inc
  65. Pharmavite LLC
  66. RTC Logic LLC
  67. Sanofi-Aventis US LLC
  68. Shire
  69. Synthelabo
  70. Wyeth-Ayerst Laboratories
  71. Affectis Pharmaceuticals AG
  72. Amarin Pharma Inc
  73. Auspex Pharmaceuticals
  74. Bayer AG
  75. Best Practice Project Management Inc
  76. BioMarin Pharmaceuticals Inc
  77. Biovail Corporation
  78. CeNeRx Bio-Pharma
  79. CNS Response Inc
  80. Compellis Pharmaceuticals
  81. Cypress Pharmaceutical Inc
  82. Dov Pharmaceuticals Inc
  83. Eisai Inc
  84. EPIX Pharmaceuticals Inc
  85. Euthymics Bioscience Inc
  86. Fabre-Kramer Pharmaceuticals Inc
  87. GenOmind LLC
  88. Gruenthal GmbH
  89. Janssen Pharmaceutica
  90. Jazz Pharmaceuticals Inc
  91. Johnson & Johnson Pharmaceutical Research & Development LLC.
  92. Knoll Pharmaceuticals Corp.
  93. Labopharm Inc
  94. Lundbeck Inc
  95. MedAvante In
  96. Merck Co. Inc
  97. Methylation Sciences
  98. Neuronetics Inc
  99. Nutrition 21
  100. PharmaStar
  101. Precision Human Biolaboratory
  102. Prexa Pharmaceuticals Inc
  103. PsychoGenics
  104. Psylin Neurosciences Inc
  105. Ridge Diagnostics Inc
  106. RCT Logic LLC
  107. Sanofi-Aventis US LLC.
  108. Sepracor Inc
  109. Schering-Plough Corporation
  110. Somaxon Pharmaceuticals Inc
  111. Somerset Pharmaceuticals Inc
  112. Takeda Pharmaceutical Company Limited
  113. Tetragenex Pharmaceuticals Inc
  114. TransForm Pharmaceuticals Inc
  115. Transcept Pharmaceuticals Inc
  116. Vanda Pharmaceuticals Inc
  117. Adamed Co
  118. Advanced Meeting Partners
  119. American Psychiatric Association
  120. American Society of Clinical Psychopharmacology
  121. Belvoir Media Group
  122. Boehringer Ingelheim GmbH
  123. Bristol-Myers Squibb
  124. Imedex LLC
  125. MGH Psychiatry Reed/Primedia
  126. MGH Psychiatry Academy/Reed Elsevier
  127. United BioSource Corp

Ask authors/readers for more resources

Major depressive disorder (MDD) profoundly affects social functioning, including the ability to enjoy social activities with peers, friends, and family members. We sought to compare changes in social functioning and depressive symptoms in the first level of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Adult outpatients (N = 2876) with diagnoses of MDD were treated using flexible doses of citalopram for up to 14 weeks. We compared the change over the course of treatment in the social activities item of the Work and Social Adjustment Scale to the change in individual items of the Quick Inventory of Depressive Symptoms-Self-Rated (QIDS-SR). Improvement in social functioning was modestly positively correlated with improvement in sad mood, concentration/decision making, involvement, and energy/fatigability. Only 16% to 22% of the variance in the change in social functioning was accounted for by these symptoms, and only 32% was accounted for by the total QIDS-SR score. In this large real-world sample of outpatients treated using citalopram, changes in depressive symptoms do not entirely explain improvements in social functioning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available